- Home
- ENTA vs FTLF Comparison
ENTA vs FTLF Comparison
Compare ENTA & FTLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- FTLF
- Stock Information
- Founded
- ENTA 1995
- FTLF 2005
- Country
- ENTA United States
- FTLF United States
- Employees
- ENTA N/A
- FTLF N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- FTLF Medicinal Chemicals and Botanical Products
- Sector
- ENTA Health Care
- FTLF Health Care
- Exchange
- ENTA Nasdaq
- FTLF Nasdaq
- Market Cap
- ENTA 154.0M
- FTLF N/A
- IPO Year
- ENTA 2013
- FTLF N/A
- Fundamental
- Price
- ENTA $5.55
- FTLF $15.41
- Analyst Decision
- ENTA Buy
- FTLF Strong Buy
- Analyst Count
- ENTA 4
- FTLF 2
- Target Price
- ENTA $17.25
- FTLF $20.50
- AVG Volume (30 Days)
- ENTA 178.5K
- FTLF 18.9K
- Earning Date
- ENTA 05-12-2025
- FTLF 05-15-2025
- Dividend Yield
- ENTA N/A
- FTLF N/A
- EPS Growth
- ENTA N/A
- FTLF 68.52
- EPS
- ENTA N/A
- FTLF 0.91
- Revenue
- ENTA $66,590,999.00
- FTLF $64,468,999.00
- Revenue This Year
- ENTA N/A
- FTLF $5.11
- Revenue Next Year
- ENTA N/A
- FTLF $7.58
- P/E Ratio
- ENTA N/A
- FTLF $17.26
- Revenue Growth
- ENTA N/A
- FTLF 22.33
- 52 Week Low
- ENTA $4.09
- FTLF $9.83
- 52 Week High
- ENTA $17.24
- FTLF $17.75
- Technical
- Relative Strength Index (RSI)
- ENTA 51.08
- FTLF 61.13
- Support Level
- ENTA $4.96
- FTLF $15.24
- Resistance Level
- ENTA $6.23
- FTLF $16.00
- Average True Range (ATR)
- ENTA 0.34
- FTLF 0.64
- MACD
- ENTA 0.01
- FTLF 0.12
- Stochastic Oscillator
- ENTA 46.46
- FTLF 71.68
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.